Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3571060 | 0.88 | HDAC1 (0.62) | HDAC1CHRM2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL12520868 | 0.86 | CHRM2 (0.57) | HDAC1CHRM2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL6692374 | 0.85 | CA1 (0.45) | HDAC1CHRM2CYP1A2CYP2C19CA1 | |
| SCHEMBL3959831 | 0.83 | MEN1 (0.63) | CHRM2CYP1A2CYP2C19CA1CA2 | |
| SCHEMBL7066938 | 0.82 | CHRM2 (0.74) | HDAC1CHRM2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL15110660 | 0.81 | CHRM2 (0.67) | HDAC1CHRM2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL13905418 | 0.81 | SLC2A4 (0.59) | CYP1A2CYP3A4CA1CA2KMT2A | |
| SCHEMBL20902781 | 0.80 | CA1 (0.65) | CYP1A2CYP2C19CA1CA2MEN1 | |
| SCHEMBL3939260 | 0.79 | MEN1 (0.56) | CYP1A2CYP2C19CA1CA2MEN1 | |
| SCHEMBL9418008 | 0.78 | HTT (0.50) | CYP1A2CYP2C19CA1CA2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | claimed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | claimed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | claimed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CETP, APOB, HDLBP | HDAC1 818/4885CHRM2 662/4885CYP1A2 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.